Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 3/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21715141 | 0.87 | FYN (0.37) | FYNGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL13170580 | 0.84 | APP (0.48) | APPMCHR1MMP2MMP3MMP9 | |
| SCHEMBL3644441 | 0.81 | NQO1 (0.56) | NQO1ACACB | |
| SCHEMBL673162 | 0.80 | APP (0.55) | APPMCHR1GRM5KCNH2ACACB | |
| SCHEMBL21715143 | 0.80 | APP (0.41) | APPFYNMCHR1MMP2MMP3 | |
| SCHEMBL14653304 | 0.80 | APP (0.46) | APPACACB | |
| SCHEMBL714294 | 0.79 | APP (0.59) | APPMCHR1GRM5KCNH2ACACB | |
| SCHEMBL12179764 | 0.78 | GRM5 (0.44) | GRM5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3846192 | 0.78 | GRM5 (0.39) | APPGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4058110 | 0.78 | LTA4H (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277169-A1 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | BIONOVO, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2010053600-A2 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | BIONOVO, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20090312274-A1 | Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases | BIONOVO, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-6818666-B2 | FOR EXAMPLE, METHYL 4-(5,5,8,8,-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2 -NAPHTHYLSULPHANYLETHYNYL)BENZOATE; USE IN HUMAN OR VETERINARY MEDICINE OR COSMETIC COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2004-11-16 | — | — | US | disclosed |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | disclosed |
| US-6441010-B2 | USEFUL AS COSMETIC FOR HAIR AND BODY HYGIENE, AND FOR TREATMENT OF DERMATOLOGICAL COMPLAINTS, WITH AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT OF RHEUMATIC OR RESPIRATORY TYPE, CARDIVASCULAR AND OPTHALMOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-08-27 | — | — | US | disclosed |
| EP-0952975-B1 | BI-AROMATIC COMPOUNDS BOUND BY A HETEROETHYNYLENE RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-07-10 | — | — | EP | disclosed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | disclosed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | disclosed |
| EP-0952975-A1 | BI-AROMATIC COMPOUNDS BOUND BY A HETEROETHYNYLENE RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development (FR) | 1999-11-03 | — | — | EP | disclosed |
| WO-1999010322-A1 | BI-AROMATIC COMPOUNDS BOUND BY A HETEROETHYNYLENE RADICAL AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 1999-03-04 | — | — | WO | disclosed |
| US-5716971-A | FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0623597-B1 | Pyridine derivatives, with potassium channel opening activity | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-10-22 | — | — | EP | disclosed |
| EP-0623597-A1 | Pyridine derivatives, with potassium channel opening activity | Takeda Chemical Industries, Ltd. (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312274-A1 | Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases | ESR2, ESR1, ESRRA | APP 3260/4885FYN 1098/4885MCHR1 348/4885 |
| US-20120277169-A1 | NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES | ESR2, ESR1, ESRRA | APP 3260/4885FYN 1098/4885MCHR1 348/4885 |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | TYR, KRT18, SCO2 | APP 2303/4885FYN 797/4885MCHR1 468/4885 |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | TYR, AHR, CYP2C19 | APP 2556/4885FYN 2181/4885MCHR1 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.